Urgent need for consensus: international survey of clinical practice exploring use of platinum-etoposide chemotherapy for advanced extra-pulmonary high grade neuroendocrine carcinoma (EP-G3-NEC).
McNamara, Mairéad G
Hubner, Richard A
Valle, Juan W
AffiliationDepartment of Medical Oncology, The Christie NHS Foundation Trust, Manchester, M20 4BX, UK
MetadataShow full item record
AbstractBACKGROUND: Platinum-etoposide (PE) chemotherapy (CH) is a globally established combination for extra-pulmonary high grade neuroendocrine carcinoma (EP-G3-NEC); the optimal schedule has not been established. METHODS: An international survey was designed, and completed by clinicians with an expertise in the field to assess consistency in clinical practice. RESULTS: Seventy-five replies were received (June-Nov'17). A minority of physicians (13; 17.6%) did not take Ki-67 or morphology (9; 12.0%) into consideration for selection of CH. Most (72; 96.0%) selected PE-CH as first-line treatment for EP-G3-NEC. CH schedules varied: cisplatin-based (37/71; 52.1%), carboplatin-based (34/71; 47.9%); intravenous etoposide (64/71; 90.1%), oral etoposide (7/71; 9.9%). Choice of second-line CH depended on time to progression on PE-based first-line: if?>?6 months, re-challenge with PE was the preferred choice (34; 45.9%); if?<?6 months, alternative combinations such as fluoropyrimidine/irinotecan (21; 29.2%) or temozolomide/capecitabine (22; 30.6%) were used. CONCLUSION: Significant variation in PE regimen employed exists. Standardising clinical practice would facilitate clinical trial development.
CitationLamarca A, Frizziero M, Barriuso J, McNamara M, Hubner R, Valle J. Urgent need for consensus: international survey of clinical practice exploring use of platinum-etoposide chemotherapy for advanced extra-pulmonary high grade neuroendocrine carcinoma (EP-G3-NEC). Clin Transl Oncol. 2018 Nov 30.
JournalClin Transl Oncol
- Neuroendocrine Cancer, Therapeutic Strategies in G3 Cancers.
- Authors: Rinke A, Gress TM
- Issue date: 2017
- Carboplatin in Combination with Oral or Intravenous Etoposide for Extra-Pulmonary, Poorly-Differentiated Neuroendocrine Carcinomas.
- Authors: Frizziero M, Spada F, Lamarca A, Kordatou Z, Barriuso J, Nuttall C, McNamara MG, Hubner RA, Mansoor W, Manoharan P, Fazio N, Valle JW
- Issue date: 2019
- Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system.
- Authors: Yamaguchi T, Machida N, Morizane C, Kasuga A, Takahashi H, Sudo K, Nishina T, Tobimatsu K, Ishido K, Furuse J, Boku N, Okusaka T
- Issue date: 2014 Sep
- A Phase III trial comparing irinotecan and cisplatin with etoposide and cisplatin in adjuvant chemotherapy for completely resected pulmonary high-grade neuroendocrine carcinoma (JCOG1205/1206).
- Authors: Eba J, Kenmotsu H, Tsuboi M, Niho S, Katayama H, Shibata T, Watanabe S, Yamamoto N, Tamura T, Asamura H, Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group., Lung Cancer Study Group of the Japan Clinical Oncology Group.
- Issue date: 2014 Apr
- Efficacy and Safety of Carboplatin and Etoposide Combination Chemotherapy for Extrapulmonary Neuroendocrine Carcinoma: A Retrospective Case Series.
- Authors: Imai H, Shirota H, Okita A, Komine K, Saijo K, Takahashi M, Takahashi S, Takahashi M, Shimodaira H, Ishioka C
- Issue date: 2016